-
Så används Nobelupptäckten i läkemedelsutveckling
Regulatoriska T-celler håller immunförsvaret i schack, en upptäckt som nu belönas med nobelpriset i fysiologi eller medicin 2025. Qiang Pan Hammarström berättar...
-
How the Nobel discovery is used in drug development
Regulatory T cells keep the immune system in check, a discovery now awarded the 2025 Nobel Prize in Physiology or Medicine. Qiang Pan Hammarström explains how t...
-
The scientist behind Novo Nordisk's obesity success: “I never stopped believing in GLP-1”
It took several years of failures in GLP-1 before Lotte Bjerre Knudsen and her colleagues found the right path – but when they did, it was a true breakthrough. ...
-
Ukraine war fuels rise of totally resistent bacteria
War-torn Ukraine is not just suffering from hostile attacks from a foreign aggressor, but also from the threat of a totally resistant and contagious bacteria.
-
Anna Törner: Yes, I Am Sick, But Not Weak
”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...
-
”Jumping genes” öppnar väg för ny behandling mot cancer
Alternativa sätt att hitta tumörantigen på tumörcellens yta kan bidra till att ta fram ny immunterapi.
-
Marie Gårdmark: Big data evidence generation drives change in the EU regulatory system
Rapid developments in technology have led to the possibility for the generation and analysis of vast volumes of data. Will the availability of big data lead to ...
-
Hon tar plats i EUFEPS
Apotekarsocietetens ordförande Märit Johansson har valts in som ledamot i EUFEPS Executive Committée.
-
Läkemedelsverket stänger av chef
En högre chef vid myndigheten sägs upp på grund av tjänsteförseelser.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten ...
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Redan prenumerant? Logga in
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.
BREAKING